Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone

LOGIN

REGISTER


Forgot your login? GET HELP

Objective: To investigate vilazodone, currently approved for major depressive disorder in adults, for generalized anxiety disorder (GAD).

Method: Three randomized, double-blind, placebo-controlled studies showing positive results for vilazodone (2,040 mg/d) in adult patients with GAD (DSM-IV-TR) were pooled for analyses; data were collected from June 2012 to March 2014. Post hoc outcomes in the pooled intent-to-treat population (n = 1,462) included mean change from baseline to week 8 in Hamilton Anxiety Rating Scale (HARS) total score, psychic and somatic anxiety subscale scores, and individual item scores; HARS response ( 50% total score improvement) and remission (total score 7) at week 8; and category shifts, defined as HARS item score 2 at baseline (moderate to very severe symptoms) and score of 0 at week 8 (no symptoms).

Results: The least squares mean difference was statistically significant for vilazodone versus placebo in change from baseline to week 8 in HARS total score (1.83, P < .0001) and in psychic anxiety (1.21, P < .0001) and somatic anxiety (0.63, P < .01) subscale scores; differences from placebo were significant on 11 of 14 HARS items (P < .05). Response rates were higher with vilazodone than placebo (48% vs 39%, P < .001), as were remission rates (27% vs 21%, P < .01). The percentage of patients who shifted to no symptoms was significant for vilazodone on several items: anxious mood, tension, intellectual, depressed mood, somatic-muscular, somatic-sensory, cardiovascular, respiratory, and autonomic symptoms (P < .05).

Conclusions: Treatment with vilazodone versus placebo was effective in adult GAD patients, with significant differences between treatment groups found on both psychic and somatic HARS items.

Trial Registration: ClinicalTrials.gov identifiers: NCT01629966, NCT01766401, NCT01844115.

Prim Care Companion CNS Disord 2016;18(2):doi:10.4088/PCC.15m01904

https://doi.org/10.4088/PCC.15m01904